# Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme

> **NCT00054496** · PHASE2 · UNKNOWN · sponsor: **The Cleveland Clinic** · enrollment: 73 (estimated)

## Conditions studied

- Brain and Central Nervous System Tumors

## Interventions

- **DRUG:** erlotinib hydrochloride

## Key facts

- **NCT ID:** NCT00054496
- **Lead sponsor:** The Cleveland Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2002-08
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 73 (ESTIMATED)
- **Last updated:** 2014-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00054496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00054496, "Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT00054496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*